b'= 155, 11%), chemoimmunotherapy (n = 32, 2%),recommended that treatments for chronic lympho-monoclonal antibody (n = 27, 2%) and chemotherapycytic leukemia and all cancers are rapidly evolving, (n = 17, 1%), the authors pointed out. so it is important to have a multidisciplinary, team-Inaddition,amongpatientswhoreceivedsinglebased approach.agent monoclonal antibody (n = 738), the most com- There are many ongoing clinical trials to improve mon second line therapy was chemoimmunotherapythe outcomes of cancer patients, so I would encourage (n = 149, 20%), followed by targeted therapy (n =patients and their doctors to see if there are studies 101, 14%), chemotherapy (n = 51, 7%), and retreat- that would benefit them, she emphasized. mentwithmonoclonalantibodyafteratreatmentFutureinvestigationsshouldincludeprospective break (n = 18, 2%), the study team explained. studiestounderstandtreatmentdecisions,quantify The study noted that a significantly greater pro- duration of treatment and specify reasons for drug portionofpatientswhoreceivedfirst-linetargeteddiscontinuation, the study authors suggested.therapy (83%) did not receive or require second-line1Ma H, OBrien S, Gupta P. Treatment Patterns and Outcomes in U.S. therapy compared to 49% of patients who receivedMilitary Veterans Diagnosed With Chronic Lymphocytic Leukemia first-line chemoimmunotherapy; P .0001.(CLL). Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):77-82. doi: For healthcare professionals who are treating U.S.10.1016/j.clml.2023.09.001. Epub 2023 Sep 7. PMID: 37743181.veterans with chronic lymphocytic leukemia, Ma Stacked bar graph of first-line therapies by year.First-Line Treatments by YearProportion (Sum)YearSource: Treatment Patterns and Outcomes in U.S. Military Veterans Diagnosed With Chronic Lymphocytic Leukemia (CLL). Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):77-82. doi: 10.1016/j.clml.2023.09.001. Epub 2023 Sep 7. PMID: 37743181.79'